Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News

Check also companies to follow in 2022 and CMN Markets for the latest stock and market trends


Main focus: Stem cell engineering for treatment of diabetes

Company stage: Clinical

Diseases: Type 1 and 2 diabetes

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: San Diego, CA, USA



Partners: CRISPR Therapeutics

Viacyte is developing engineered stem cells in order to treat diabetes. The company has an ongoing collaboration with CRISPR Therapeutics, for which the companies seek to develop a next generation stem cell product for all type 1 diabetes and insulin-requiring type 2 diabetes patients. The programme is currently in a research phase.


HashtagViaCyte, Inc.

Company: Viacyte
Search CRISPR Medicine